Insights from 2023 ASH Annual Meeting

 

Insights from 2023 ASH Annual Meeting
V

The Best of CLL: Highlights & Key Takeaways

By Insights from 2023 ASH Annual Meeting FEATURING Victor Yazbeck
By Insights from 2023 ASH Annual Meeting FEATURING Victor Yazbeck
593 views
January 24, 2024

Chapters

FDA Approval & Response Rates for Pirtobrutinib

00:00

Zanubrutinib vs. Ibrutinib: CLL PFS Outcomes

02:45

Ibrutinib & Venetoclax Benefits & Retreatment Results

05:01

Comments 0
Login to view comments. Click here to Login

Featured Video

04:26
Pharmacosmos Hematology

An Introduction to an IV iron replacement therapy

Feat. H. Bahrain

Featured Video

19:25
Pfizer Hematology

Moving Forward in Stage III/IV Classical Hodgkin Lymphoma

Feat. A. Ip
Leukemia
05:08

Zanubrutinib in 1L CLL: A Biomarker Analysis From the Phase 3 SEQUOI…

Insights from 2023 ASH Annual Meeting

P. Ghia

115 views
06:13

FLT3-ITD Mutated AML: PROs From the QuANTUM-First Trial of Quizartin…

Insights from 2023 ASH Annual Meeting

E. Oliva

152 views
20:28

Clinically-Relevant Updates in ALL in Adults

Insights from 2023 ASH Annual Meeting

R. Cassaday

261 views
08:45

The Best of CLL: Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

V. Yazbeck

593 views
22:37

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

2.2K views
21:20

The Future Paradigm of HMA + Ven or Targeted Agents in AML: Sequenci…

Insights from 2023 ASH Annual Meeting

J. Watts

179 views
06:43

ASH 2023 Insights: "NPM1-Mutated Myeloid Neoplasms - Outcomes With H…

Insights from 2023 ASH Annual Meeting

G. Montalban Bravo

113 views
09:01

ASH 2023 Insights: "Asciminib + Imatinib, Nilotinib, or Dasatinib in…

Insights from 2023 ASH Annual Meeting

J. Cortés

88 views
11:36

ASH 2023 Insights: "Maintenance Rux Is Associated With Low Rates of …

Insights from 2023 ASH Annual Meeting

Z. DeFilipp

32 views
09:09

ASH 2023 Insights: "Venetoclax + Pegcrisantaspase in R/R AML - Overc…

Insights from 2023 ASH Annual Meeting

Y. Liu

60 views
13:15

ASH 2023 Insights: "Bezuclastinib (CGT9486), a Novel KIT D816V TKI, …

Insights from 2023 ASH Annual Meeting

P. Vachhani

49 views
13:07

ASH 2023 Insights: "Venetoclax With Azacitidine for Pts With Treatme…

Insights from 2023 ASH Annual Meeting

J. Garcia

364 views
06:49

ASH 2023 Insights: "Mini-Hyper-CVD Plus Venetoclax for Older Adults …

Insights from 2023 ASH Annual Meeting

M. Luskin

179 views
07:43

ASH 2023 Insights: "Venetoclax With Inotuzumab Ozogamicin for R/R AL…

Insights from 2023 ASH Annual Meeting

M. Luskin

25 views
04:45

ASH 2023 Insights: "The Impact of Inotuzumab Ozogamicin Treatment on…

Insights from 2023 ASH Annual Meeting

I. Aldoss

164 views
05:38

ASH 2023 Insights: "Revumenib Monotherapy in Pts With R/R KMT2Ar Acu…

Insights from 2023 ASH Annual Meeting

I. Aldoss

101 views
09:19

ASH 2023 Insights: "MRD-Guided Acalabrutinib, Venetoclax and Obinutu…

Insights from 2023 ASH Annual Meeting

M. Fürstenau

61 views
13:31

ASH 2023 Insights: "COVALENT-101 Study - Covalent Menin Inhibitor BM…

Insights from 2023 ASH Annual Meeting

J. Lancet

86 views
01:44

ASH 2023 Insights: "Optimizing Outcomes With Myeloablative Condition…

Insights from 2023 ASH Annual Meeting

C. Oliai

19 views
07:55

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes Among Pat…

Insights from 2023 ASH Annual Meeting

E. Atallah

635 views
10:08

Comparison of Venetoclax Based Treatments for Patients With R/R CLL

Insights from 2023 ASH Annual Meeting

B. Heyman

296 views
18:27

FLT3-ITD Mutated AML: QuANTUM-First - Safety by Treatment Phase and …

Insights from 2023 ASH Annual Meeting

H. Erba

208 views
18:01

ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Primetim…

Insights from 2023 ASH Annual Meeting

J. Rhodes

329 views
04:21

ASH 2023 Insights: "Improving Long-Term Outcomes With Intensive Indu…

Insights from 2023 ASH Annual Meeting

C. Röllig

135 views
03:03

ASH 2023 Insights: "Olverembatinib (HQP1351) Overcoming Ponatinib an…

Insights from 2023 ASH Annual Meeting

E. Jabbour

125 views
11:00

ASH 2023 Insights: "Oral Decitabine/Cedazuridine (ASTX727) & Venetoc…

Insights from 2023 ASH Annual Meeting

H. Atluri

29 views
11:02

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Prednisone…

Dana-Farber Cancer Institute

M. Luskin

207 views
08:32

ASH 2023 Insights: "ALLG CML13 ASCEND-CML Study - Asciminib Treatmen…

Insights from 2023 ASH Annual Meeting

D. Yeung

124 views
14:40

ASH 2023 Insights: "AYAs With ALL - Treatment Approaches and Ongoing…

Insights from 2023 ASH Annual Meeting

E. Curran

54 views
14:10

ASH 2023 Insights: "Relapse Incidence Post Unrelated alloSCT With Po…

Insights from 2023 ASH Annual Meeting

A. Nagler

30 views
06:56

Efficacy of Ibrutinib Arms Across ALPINE and ELEVATE-RR Trials in R/…

Insights from 2023 ASH Annual Meeting

M. Shadman

824 views
07:04

Impact of Ibrutinib Dose Reduction on Duration of Therapy in Patient…

Insights from 2023 ASH Annual Meeting

M. Shadman

408 views
08:11

ASH 2023 Insights: "A Comparison of HMAs Combined With Ivosidenib or…

Insights from 2023 ASH Annual Meeting

A. Ambinder

50 views
08:26

CLL/SLL Treatment With Post-cBTKi Pirtobrutinib: 30 Months Follow-Up…

Insights from 2023 ASH Annual Meeting

J. Woyach

398 views
06:17

ASH 2023 Insights: "Revumenib Maintenance Therapy Following Revumeni…

Insights from 2023 ASH Annual Meeting

A. Zucenka

71 views
05:12

R/R CLL Treated With Fixed-Duration Pirtobrutinib Combined With Vene…

Insights from 2023 ASH Annual Meeting

N. Shah

410 views
07:06

ASH 2023 Insights: "Effectiveness of Venetoclax-Based Therapy After …

Insights from 2023 ASH Annual Meeting

N. Ghosh

147 views
08:18

ASH 2023 Insights: "Effect of Ibrutinib Flexible Dosing Strategies o…

Insights from 2023 ASH Annual Meeting

N. Ghosh

101 views
07:22

ASH 2023 Insights: "Hypertension in Pts With CLL and Other Heme Mali…

Insights from 2023 ASH Annual Meeting

A. Ferrajoli

172 views
09:38

ASH 2023 Insights: "A Long-Term Analysis of Lenalidomide & Rituximab…

Insights from 2023 ASH Annual Meeting

C. Chen

31 views
07:18

ASH 2023 Insights: "A Study of Venetoclax Added to Ibrutinib to Elim…

Insights from 2023 ASH Annual Meeting

K. Rogers

70 views
07:32

ASH 2023 Insights: "Understanding Differential Technologies for Dete…

Insights from 2023 ASH Annual Meeting

J. Cloos

83 views
10:32

FLT3-ITD Mutated AML: Quizartinib, Venetoclax, & Decitabine Triple C…

Insights from 2023 ASH Annual Meeting

M. Yilmaz

142 views
07:11

ASH 2023 Insights: "Results From a Ph1 Study of the All-Oral Regimen…

Insights from 2023 ASH Annual Meeting

M. Amaya

158 views
06:57

TN-CLL/SLL: Combination Treatment With Sonrotoclax (BGB-11417), a 2n…

Insights from 2023 ASH Annual Meeting

M. Ann Anderson

182 views
05:28

ASH 2023 Insights: "Performance of the Molecular International Progn…

Insights from 2023 ASH Annual Meeting

K. Chien

73 views
10:38

ASH 2023 Insights: "Venetoclax Improves Response Rates But Not Survi…

Insights from 2023 ASH Annual Meeting

D. Tremblay

37 views